Impact of losartan on stroke risk in hypertensive patients in primary care

Clinical Drug Investigation

Volumn 27, Issue 5, 2007, Pages 347-355

  Bestehorn, K ^a,b   Wahle, Klaus ^c  

^a MSD Sharp and Dohme GmbH   (Germany)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^c German Primary Care Physician Association (BDA)   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROCHLOROTHIAZIDE; LOSARTAN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYST; DEMOGRAPHY; DIABETES MELLITUS; FEMALE; GASTROINTESTINAL DISEASE; GERMANY; HEART DISEASE; HEART LEFT VENTRICLE HYPERTROPHY; HEPATOBILIARY DISEASE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INFECTION; INFESTATION; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM DISEASE; MENTAL DISEASE; METABOLIC DISORDER; MULTICENTER STUDY; NEUROLOGIC DISEASE; NUTRITIONAL DISORDER; PHASE 4 CLINICAL TRIAL; POLYP; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; QUESTIONNAIRE; RESPIRATORY TRACT DISEASE; RISK FACTOR; SCORING SYSTEM; STROKE; THORAX DISEASE; URINARY TRACT DISEASE; VASCULAR DISEASE;

EID: 34249060403     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200727050-00006     Document Type: Article

References (16)

1. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997; 349 (9064): 1498-504
2. Goldstein LB, Adams R, Alberts MJ, et al. Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council. Stroke 2006; 37: 1583-633
3. Kjeldsen SE, Julius S, Hedner T, et al. Stroke is more common than myocardial infarction in hypertension: analysis based on 11 major randomized intervention trials. Blood Press 2001; 10 (4): 190-2
4. D'Agostino RB, Wolf PA, Belanger AJ, et al. Stroke risk profile: adjustment for antihypertensive medication. The Framingham Study. Stroke 1994; 25 (1): 40-3
5. Moen MD, Wagstaff AJ. Losartan: a review of its use in stroke risk reduction in patients with hypertension and left ventricular hypertrophy. Drugs 2005; 65 (18): 2657-74
6. Institut für Praxisforschung (PRAFO) im BDA [online]. Available from: http://www.hausarzt-bda.de/private/020/040/pravo.html [Accessed 2006 Jul 12]
7. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359 (9311): 995-1003
8. Kizer JR, Dahlof B, Kjeldsen SE, et al. Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension study. Hypertension 2005; 45 (1): 46-52
9. Ferrario CM. The role of angiotensin antagonism in stroke prevention in patients with hypertension: focus on losartan. Curr Med Res Opin 2004; 20 (11): 1797-804
10. Guidelines committee. European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011-53
11. International Diabetes Federation. Hypertension in people with type 2 diabetes: knowledge-based diabetes-specific guidelines. Diabet Med 2003; 20 (12): 972-87
12. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. J Am Med Ass 2003; 289 (19): 2560-71
13. Hasford J, Mimran A, Simons W. A population-based European cohort study of persistence in newly diagnosed hypertensive patients. J Hum Hypertens 2002; 16 (8): 569-75
14. Law MR, Wald NJ, Morris JK, et al. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. Brit Med J 2003; 326 (7404): 1427-31
15. Pittrow D, Kirch W, Bramlage P, et al. Patterns of antihypertensive drug utilization in primary care. Eur J Clin Pharmacol 2004; 60 (2): 135-42
16. Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 2000; 342 (25): 1887-92